• We treated 193 patients either intravenously (94) or subcutaneously (99) for at least 5 days with porcine intestinal mucosal heparin and followed them up prospectively with frequent platelet counts to determine the incidence of heparin-related thrombocytopenia and arterial thrombosis. None of the patients in the study developed severe thrombocytopenia (platelet count, 100 × 109/L) or arterial thrombosis. Eight patients had a platelet count of 100 to 140×109/L on one occasion, with a count of 140 × 109/L on the subsequent measurement. The mean (± SD) values of the initial and lowest platelet counts during therapy in all patients were 288±100×109/L and 253±88× 109/L, respectively, with the lowest counts occurring on day 4.1 ± 4.2. A least-squares line was computed for each patient to fit the day and counts; the slopes were significantly different from zero and negative in 7.8% of patients and positive in 14.5%. This multicenter study confirms the reports that the incidence of heparinrelated severe thrombocytopenia and arterial thrombosis is distinctly low in patients treated with porcine-mucosal heparin.
(Arch Intern Med. 1989;149:1285-1288)
Rao AK, White GC, Sherman L, Colman R, Lan G, Ball AP. Low Incidence of Thrombocytopenia With Porcine Mucosal Heparin: A Prospective Multicenter Study. Arch Intern Med. 1989;149(6):1285–1288. doi:10.1001/archinte.1989.00390060039008
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.